source
- Immunovant halts cutaneous lupus program after phase 2 failureImmunovant announced it is discontinuing development of its anti-FcRn antibody IMVT-1402 for cutaneous lupus erythematosus. The decision follows a mid-phase trial that did not meet its primary end…
- Immunovant halts lupus program after Phase 2b trial fails to meet efficacy endpointsImmunovant announced that its anti‑FcRn drug imeroprubart (IMVT‑1402) did not achieve the primary endpoint in a Phase 2b study in patients with cutaneous lupus erythematosus. The double‑blind tria…